Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Gilteritinib

Gilteritinib
Gilteritinib (ASP2215) is a potent inhibitor of FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preclinical studies, gilteritinib demonstrated strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 clinical trials for acute myeloid leukemia.
Catalog No. T4409Cas No. 1254053-43-4
Select Batch
Purity:99.74%
Contact us for more batch information

Resource Download

Gilteritinib

Catalog No. T4409Cas No. 1254053-43-4

Gilteritinib (ASP2215) is a potent inhibitor of FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preclinical studies, gilteritinib demonstrated strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 clinical trials for acute myeloid leukemia.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
1 mg$34In Stock
2 mg$50In Stock
5 mg$82In Stock
10 mg$123In Stock
25 mg$197In Stock
50 mg$291In Stock
100 mg$457In Stock
500 mg$1,060In Stock
1 g$1,430In Stock
Bulk & Custom
Add to Cart

Related Compound Libraries of "Gilteritinib"

Product Introduction

Bioactivity
Description
Gilteritinib (ASP2215) is a potent inhibitor of FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preclinical studies, gilteritinib demonstrated strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 clinical trials for acute myeloid leukemia.
Targets&IC50
EML4-ALK:1.2 nM, c-Kit:230 nM, Axl:0.73 nM, FLT3:0.29 nM, TYK1/LTK:0.35 nM
In vitro
Gilteritinib (ASP2215) has been tested against 78 tyrosine kinases, demonstrating strong inhibitory effects on FLT3, leukocyte tyrosine kinase (LTK), anaplastic lymphoma kinase (ALK), and AXL kinases, reducing their activity by over 50% at a concentration of 1 nM. Particularly, Gilteritinib exhibits an IC50 of 0.29 nM for FLT3, making it approximately 800 times more effective against FLT3 than against c-KIT, for which the IC50 is 230 nM. Furthermore, it significantly inhibits eight out of the tested kinases at concentrations up to 5 nM, including TRKA, ROS, RET, and MER, in addition to those previously mentioned. In cell-based assays, Gilteritinib effectively suppresses the growth of MV4-11 and MOLM-13 cells, which naturally express FLT3-ITD mutations, with mean IC50 values of 0.92 nM and 2.9 nM, respectively, upon 5-day treatment. This antiproliferative effect correlates with the reduction of FLT3 phosphorylation and the downstream inhibition of ERK, STAT5, and AKT phosphorylation. A study exploring its impact on AXL inhibition in MV4-11 cells that express exogenous AXL revealed dose-dependent decreases in phosphorylated AXL levels following 4 hours of treatment, highlighting Gilteritinib's potent inhibitory action on both FLT3 and AXL signaling pathways.
In vivo
In MV4-11 xenografted mice, administration of Gilteritinib (ASP2215) orally at 10 mg/kg for four days markedly elevates its tumor concentration, achieving levels over 20-fold higher than in plasma. A 28-day course of Gilteritinib treatment demonstrates dose-dependent suppression of MV4-11 tumor growth, with complete regression observed at dosages exceeding 6 mg/kg. Additionally, Gilteritinib significantly reduces tumor presence in the bone marrow and extends the survival of mice that have undergone intravenous transplant with MV4-11 cells.
Kinase Assay
The kinase inhibitory activity of Gilteritinib is tested against a panel of 78 tested kinases using ATP concentrations that are approximately equal to the Km value for each kinase in a TK-ELISA or off-chip mobility shift assay. Initially, two concentrations of Gilteritinib (1 nM and 5 nM) are tested to assess each compound's inhibitory effect on TK activity. Further studies are then conducted using a dose range of Gilteritinib to determine IC50 values for kinases in which activity is inhibited by >50% with 1 nM Gilteritinib as well as for c-KIT. TK-ELISA and MSA assays are used to conduct IC50 studies for FLT3, LTK, AXL, and c-KIT; the HTRF KinEASE-TK assay is performed to assess the IC50 value of echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK)
Cell Research
Gilteritinib is dissolved in DMSO and stored, and then diluted with appropriate media before use.The effect of Gilteritinib on MV4-11 and MOLM-13 cells is assessed using the CellTiter-Glo Luminescent Cell Viability Assay. Subsequent studies are conducted to examine the effect of Gilteritinib and Quizartinib on Ba/F3 cells expressing either FLT3-ITD, FLT3-D835Y, FLT3-ITD-D835Y, FLT3-ITD-F691 L, or FLT3-ITD-F691I. MV4-11 and MOLM-13 cells are treated with DMSO or increasing concentrations of Gilteritinib (0.01, 0.1, 1, 10, and 100 nM) for 5 days, and cell viability is measured using CellTiter-Glo
Animal Research
MiceAntitumor activity is evaluated in nude mice transplanted with MV4-11 AML cells. The pharmacokinetics in xenografted mice is also investigated. MV4-11 xenografted-mice are treated with oral administration of Gilteritinib at 10 mg/kg for 4 days. Treatment of Gilteritinib for 28 days results in dose-dependent inhibition of MV4-11 tumor growth and induces complete tumor regression at more than 6 mg/kg
AliasASP2215
Chemical Properties
Molecular Weight552.71
FormulaC29H44N8O3
Cas No.1254053-43-4
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 1 mg/mL
Ethanol: 4 mg/mL (7.2 mM)
H2O: Insoluble
10% DMSO+90% Saline: 0.2 mg/mL (0.36 mM), Working solution is recommended to be prepared and used immediately.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Gilteritinib | purchase Gilteritinib | Gilteritinib cost | order Gilteritinib | Gilteritinib chemical structure | Gilteritinib in vivo | Gilteritinib in vitro | Gilteritinib formula | Gilteritinib molecular weight